Individualized Precision Prostate Biopsy Strategy for Patients With PI-RADS Score 2: A Retrospective Multicenter Study.
[BACKGROUND] Prostate biopsy is currently the most common method of diagnosing prostate cancer (PCa).
APA
Xu Z, Liang Y, et al. (2026). Individualized Precision Prostate Biopsy Strategy for Patients With PI-RADS Score 2: A Retrospective Multicenter Study.. The Prostate, 86(5), 534-541. https://doi.org/10.1002/pros.70116
MLA
Xu Z, et al.. "Individualized Precision Prostate Biopsy Strategy for Patients With PI-RADS Score 2: A Retrospective Multicenter Study.." The Prostate, vol. 86, no. 5, 2026, pp. 534-541.
PMID
41410022
Abstract
[BACKGROUND] Prostate biopsy is currently the most common method of diagnosing prostate cancer (PCa). However, excessive biopsies not only cause physical and psychological pain to patients, but also increase the healthcare burden. We aimed to provide a biopsy strategy for patients with PI-RADS score 2 to improve the detection rate of clinically significant PCa (csPCa) while minimizing unnecessary prostate biopsies.
[METHODS] This study retrospectively collected clinical data from patients undergoing prostate biopsy from three medical centers in China. The KD cohort was used as the primary analysis cohort, and the ZD and YJS cohorts were used as external validation cohorts. Diagnostic capacity of clinical variables was assessed using the receiver operating characteristic (ROC) curves and area under the curve (AUC) and compared with DeLong test. By plotting the relationship between csPCa risk and prostate-specific antigen density (PSAD) values using a locally estimated scatterplot smoothing(loess) function, the PSAD cutoff value corresponding to a clinically reasonable csPCa risk is determined. Prostate biopsy strategies are represented as simple decision tree diagrams. This study used csPCa as the only study endpoint.
[RESULTS] By grouping patients with a cut-off value of PSAD ≥ 0.46 ng/ml, the detection rate of csPCa in the KD cohort of patients with a PI-RADS score of 2 increased from an initial 3.7-18.7%. And according to our proposed strategy would reduce unnecessary prostate biopsy by 86.5%, and at the same time could reduce the detection of clinically insignificant PCa (cisPCa) by 96.7%, at the cost of missing 1.3% of csPCa. The similar diagnostic performance was also shown in the ZD and YJS cohorts.
[CONCLUSIONS] The individualized precision prostate biopsy strategy is developed in this study, which can be used to make optimal decisions when faced with low-risk PCa (PI-RADS score 2) patients.
[METHODS] This study retrospectively collected clinical data from patients undergoing prostate biopsy from three medical centers in China. The KD cohort was used as the primary analysis cohort, and the ZD and YJS cohorts were used as external validation cohorts. Diagnostic capacity of clinical variables was assessed using the receiver operating characteristic (ROC) curves and area under the curve (AUC) and compared with DeLong test. By plotting the relationship between csPCa risk and prostate-specific antigen density (PSAD) values using a locally estimated scatterplot smoothing(loess) function, the PSAD cutoff value corresponding to a clinically reasonable csPCa risk is determined. Prostate biopsy strategies are represented as simple decision tree diagrams. This study used csPCa as the only study endpoint.
[RESULTS] By grouping patients with a cut-off value of PSAD ≥ 0.46 ng/ml, the detection rate of csPCa in the KD cohort of patients with a PI-RADS score of 2 increased from an initial 3.7-18.7%. And according to our proposed strategy would reduce unnecessary prostate biopsy by 86.5%, and at the same time could reduce the detection of clinically insignificant PCa (cisPCa) by 96.7%, at the cost of missing 1.3% of csPCa. The similar diagnostic performance was also shown in the ZD and YJS cohorts.
[CONCLUSIONS] The individualized precision prostate biopsy strategy is developed in this study, which can be used to make optimal decisions when faced with low-risk PCa (PI-RADS score 2) patients.
같은 제1저자의 인용 많은 논문 (5)
- SIRT Combined with Targeted Therapy and Immunotherapy Achieves Sustained Complete Remission in Advanced Hepatocellular Carcinoma: A Case Report.
- USP7 deubiquitinates Aurora B and promotes hepatocellular carcinoma progression.
- Berberine-Mediated BCRP Inhibition Enhances Systemic Exposure of Rhein: A Study to Unravel the Pharmacokinetic Basis of Synergy in Da-Huang-Xiao-Shi Decoction.
- The ATF5-GPER1 axis drives female protection in hepatocellular carcinoma through dual tumor-suppressive and immune-modulatory mechanisms.
- Discovery of novel and potent harringtonine derivative P2 via systematic structure-activity Optimization: Semi-Synthesis, anti-leukemia activity, and mechanism study.